by I grew up in a house where TB was whispered about like a ghost. My grandmother had survived it in the 1970s — she had the scar on her lung to prove it. Back then, it was the disease of crowded streets and poor families, something we were all quietly grateful to have “moved past.” Progress was being made. Numbers were falling. We thought we were winning.
Then 2023 happened.
The World Health Organization dropped a report that honestly stopped me in my tracks. TB didn’t just persist — it surged. And the numbers weren’t just bad. They were historically bad.
The Number That Should Have Been Front-Page News
Here’s what the WHO’s Global Tuberculosis Report 2024 confirmed (covering data from 2023): 8.2 million people were newly diagnosed with TB in 2023. That’s the highest figure recorded since WHO began global TB monitoring back in 1995. Nearly 30 years of surveillance data, and 2023 landed at the very top of the worst column.
But the newly diagnosed figure only tells part of the story. The total estimated number of people who actually got sick with TB — including those never officially diagnosed — reached 10.8 million. That’s nearly 11 million human beings walking around, coughing, losing weight, wondering why they’re tired all the time… many of them never seeing a doctor.
And the death toll? 1.25 million people died from TB in 2023. That’s roughly the entire population of a mid-sized city — gone — from a disease that is, in most cases, preventable and treatable.
I’ll be honest: when I first read that statistic, I had to put my phone down and just sit with it for a minute.
How Did We Get Here? The COVID Hangover Nobody Talks About
This is the part that makes the whole story click.
When COVID-19 hit in 2020, healthcare systems worldwide essentially pivoted. TB clinics closed or reduced capacity. Contact tracing for tuberculosis stopped. People with persistent coughs — the classic TB warning sign — were either too scared to go to hospitals, or hospitals were too overwhelmed to properly screen them.
The result? Millions of TB cases went undiagnosed during 2020 and 2021. Those people kept spreading the bacteria. Others kept getting infected. And TB, unlike COVID, has a slow and sneaky natural history — it can take months or even years from the moment of infection to the development of active disease.
So what happened in 2023 is essentially a delayed bill coming due. The disruptions from the pandemic didn’t vanish when the world “reopened.” They just showed up later, in a different disease.
Between 2020 and 2023, the global incidence rate of tuberculosis rose by an estimated 4.6 percent. That might sound small in isolation, but when you’re talking about a disease that already infects tens of millions annually, even small percentage climbs translate into enormous human suffering.
Who Is Getting Hit the Hardest?
The WHO data makes it painfully clear that this is not a disease spread evenly around the world. Thirty mostly low- and middle-income countries account for 87% of the global TB burden. Five countries — India, Indonesia, China, the Philippines, and Pakistan — together carry 56% of all global TB cases.
Let me put Pakistan into sharper focus, because if you’re reading this from South Asia, this is especially close to home. Pakistan is ranked fifth among high-burden TB countries globally, with an estimated 510,000 new TB cases every year. That’s a staggering number. And the challenges are layered: a 60% funding gap in TB programs, fragmented data systems across provinces, and over 84% of healthcare services being delivered through the private sector — which historically has had weaker TB screening and reporting.
Meanwhile, children aren’t being spared either. Twelve percent of all TB cases globally are children and young adolescents. That’s not a footnote. That’s roughly 1 million kids a year.
In terms of gender, 55% of cases were men, 33% women. That gap is partly explained by behavioral risk factors like smoking and alcohol use being more common in men — but it doesn’t mean women are safe. Women in high-burden countries often face additional barriers: stigma, limited access to healthcare, economic dependence that makes treatment adherence harder.
The Five Risk Factors That Are Fueling This
TB doesn’t just randomly attack people. The WHO identified five major drivers behind the surge in new cases:
1. Undernutrition — This one hits close to home in South Asia and sub-Saharan Africa. When your immune system is weakened from not getting enough food, TB bacteria that might otherwise stay dormant become active. The TB-hunger connection is deeply intertwined with poverty.
2. HIV infection — People living with HIV have compromised immune systems, making them vastly more susceptible to active TB disease. About 6.1% of all new TB cases in 2023 were co-infected with HIV.
3. Alcohol use disorders — Chronic alcohol use suppresses immune function and is strongly associated with higher TB rates, particularly in men.
4. Smoking — One of the more underappreciated risk factors. Smoking damages the lung’s natural defense mechanisms, creating an easier path for TB bacteria.
5. Diabetes — This one is growing in importance. As diabetes rates rise across South Asia and other developing regions, so does TB risk. A systematic review of South Asian studies found that roughly 21% of TB patients also had diabetes — a truly alarming overlap.
Addressing these factors requires more than just handing out antibiotics. It requires poverty reduction, nutrition programs, HIV management, and public health messaging that reaches the most vulnerable people.
The Drug-Resistance Problem Is Getting Scary
Here’s where the story takes a genuinely frightening turn.
Standard TB is bad enough. But multidrug-resistant TB (MDR-TB) — a strain that doesn’t respond to the two most powerful first-line antibiotics — is becoming a serious global threat. In 2023, approximately 400,000 new TB cases were MDR-TB or rifampicin-resistant TB.
Treating drug-resistant TB is extraordinarily difficult. The regimens are longer, more toxic, more expensive, and harder to access in the countries that need them most. In many resource-limited settings, the success rate for MDR-TB treatment sits below 60%.
How does drug resistance emerge? Mostly from incomplete treatment. When patients stop taking their antibiotics partway through — because they feel better, because drugs ran out, because they couldn’t afford transportation to the clinic — the bacteria that survive are the hardiest ones. Over time, those resistant strains become dominant.
It’s a public health problem that starts at the individual level and spirals outward. One person’s incomplete treatment course can eventually fuel a drug-resistant outbreak that affects entire communities.
What You Should Actually Know About TB Symptoms (and Why People Miss It)
One of the reasons TB spreads so easily is that early symptoms are genuinely easy to ignore or misattribute.
The classic warning signs include:
- A persistent cough lasting more than two to three weeks (sometimes with blood)
- Unexplained weight loss
- Night sweats
- Persistent low-grade fever
- Fatigue and weakness
- Chest pain or pain when breathing
The problem? These symptoms look a lot like a bad flu, chronic bronchitis, or general exhaustion. In communities where healthcare access is limited and stigma around TB is strong, people delay seeking diagnosis for months — sometimes over a year. By the time they get tested, they’ve already been infectious for a long time.
If you or anyone around you has a cough that’s lasted more than two weeks and isn’t getting better, please get a sputum test done. It’s simple, it’s often free in government facilities, and it can genuinely save your life — and the lives of people you love.
The Funding Crisis Nobody Wants to Talk About
Here’s a fact that should make everyone angry.
At the 2023 United Nations High-Level Meeting on TB, member states agreed to mobilize $22 billion per year for TB prevention, diagnosis, and treatment in low- and middle-income countries by 2027. A clear, ambitious, necessary target.
The total funding actually available in 2023? $5.7 billion. That’s barely 26 cents on every promised dollar.
And global TB research funding? Around $1 billion — one-fifth of the $5 billion annual target needed to develop new vaccines, diagnostics, and treatments.
The BCG vaccine — the one most of us received at birth — is effective at preventing severe TB in children, but provides limited protection against pulmonary TB in adults. That’s the form of TB that spreads from person to person and kills the most people. New vaccine candidates are in development, including one called M72/AS01E that showed encouraging results in phase 2 trials. But without funding, those candidates stall.
The WHO’s Director-General Tedros Adhanom Ghebreyesus said it plainly: “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it, and treat it.”
He’s right. The tools exist. The will and the money don’t, at the scale needed.
What You Can Actually Do
I know it’s easy to read a piece like this and feel overwhelmed — like this is a problem too big for any individual to touch. But that’s exactly how diseases like TB win. They thrive on inertia and silence.
Here’s what genuinely matters at the ground level:
Get tested if you have symptoms. Especially if you’ve been around someone with TB, or if you live in a high-density setting. TB testing is widely available through government healthcare programs in Pakistan, India, and other high-burden countries — often completely free.
Complete your treatment if you’re diagnosed. The standard treatment course for drug-susceptible TB is 6 months. Not 6 weeks. Not until you feel better. Six months. Missing doses or stopping early is exactly how drug resistance develops.
Talk about it openly. TB stigma kills people. When families keep sick members hidden to avoid social judgment, those people don’t get treated and keep infecting others. The disease spreads through silence.
Support organizations working on TB. Groups like the Stop TB Partnership, Médecins Sans Frontières, and national TB control programs need funding and political pressure. Awareness matters.
Reduce risk factors. If you smoke, stopping improves your lung defenses. Managing diabetes reduces your TB susceptibility. Good nutrition — even modest improvements — strengthens immune response.
There Is Actually Some Hope
I want to end this on something other than pure alarm, because the full picture isn’t entirely dark.
The treatment success rate for standard drug-susceptible TB remains high at 88%. That’s a genuinely impressive number. When people get diagnosed and actually complete treatment, most of them recover.
The success rate for MDR-TB treatment has also climbed to 68% — still far too low, but improving due to shorter, less toxic drug regimens.
The diagnostic gap — the difference between estimated cases and actually diagnosed cases — fell from 4 million during the peak pandemic years to 2.7 million in 2023. That means more people are getting diagnosed and treated than before.
And there are 15 TB vaccine candidates in the development pipeline, with six of them currently in phase 3 trials in the highest-burden countries. The political declaration from the 2023 UN meeting called for at least one new effective TB vaccine by 2028. That’s an ambitious but potentially achievable target.
The global increase in TB incidence also appears to be slowing. Based on current trends, we may see stabilization or even a reversal in the next year or two — if healthcare systems continue recovering from pandemic-era disruptions.
Where We Actually Stand
TB in 2023 reclaimed the grim title it briefly lost to COVID-19: the world’s leading infectious disease killer from a single pathogen. That’s a sentence I genuinely didn’t expect to be writing in 2024.
My grandmother survived TB in a decade with far fewer tools, far fewer drugs, far less understanding. The fact that we have those tools now — and are still losing 1.25 million people a year — is a policy failure as much as it is a medical one.
Watching these numbers come out, I keep thinking about all the families quietly dealing with this in places like Lahore, Jakarta, Manila, and Lagos — coughing through the night, putting off the clinic visit one more week, waiting until it’s worse. TB doesn’t wait. And neither should we.
Sources: WHO Global Tuberculosis Report 2024 (covering 2023 data), CIDRAP, Pulmonology Advisor, PMC/NCBI research publications on TB in Pakistan and South Asia.
